Date: 2011-12-22
Type of information: Grant
Company: PTC Therapeutics (UK)
Investors: The Wellcome Trust (UK)
Amount: $5 million
Funding type: grant
Planned used: This funding will support PTC Therapeutics efforts to develop novel antibiotics to treat infections caused by multidrug-resistant Gram-negative bacteria. The company has identified a novel structural class of molecules that have potent activity against Gram-negative bacteria that are resistant to marketed antibiotics. The anti-infective program at PTC is currently in lead optimization and advancing towards identifying a Development Candidate.
Others: PTC Therapeutics has announced the receipt of a $5 million Seeding Drug Discovery (SDD) Award from The Wellcome Trust to support the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria. PTC previously received a $5.4 million SDD Award from the Wellcome Trust to support its BMI1 oncology program.
Therapeutic area: Infectious diseases
